日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

A multi-country time and motion study to describe the experience and burden associated with the treatment of Fabry disease with enzyme replacement therapy with agalsidase alfa and agalsidase beta

一项多国时间动作研究，旨在描述使用阿加糖酶α和阿加糖酶β进行酶替代疗法治疗法布里病患者的经验和相关负担。

期刊:Orphanet Journal of Rare Diseases
影响因子:3.5
doi:10.1186/s13023-025-03707-2
Keyzor, Ian; Martins, Ana Maria; Uçar, Sema Kalkan; Yamakawa, Hiroyuki; Chien, Yin-Hsiu; Arslan, Nur; Niu, Dau-Ming; Tümer, Leyla; Baldock, Laura; Shohet, Simon; Giuliano, Joseph D
发表日期：2025
文献求助 收藏

A national-scale sampled temperate fuel moisture database

全国范围的温带燃料湿度采样数据库

期刊:Scientific Data
影响因子:6.9
doi:10.1038/s41597-024-03832-w
Ivison, Katy; Little, Kerryn; Orpin, Alice; Lewis, C H M; Dyer, Niamh; Keyzor, Lily; Everett, Luke; Stoll, Erin; Andersen, Roxane; Graham, Laura J; Kettridge, Nicholas
发表日期：2024
文献求助 收藏

Minimal clinically important differences in six-minute walking distance in late-onset Pompe disease

晚发型庞贝病患者六分钟步行距离的临床重要差异极小

期刊:Orphanet Journal of Rare Diseases
影响因子:3.5
doi:10.1186/s13023-024-03156-3
Claeys, Kristl G; Kushlaf, Hani; Raza, Syed; Hummel, Noemi; Shohet, Simon; Keyzor, Ian; Kopiec, Agnieszka; Graham, Ryan; Fox, Brian; Schoser, Benedikt
发表日期：2024
文献求助 收藏

Validation of the Patient-Reported Outcomes Measurement Information System (PROMIS(®)) physical function questionnaire in late-onset Pompe disease using PROPEL phase 3 data

利用 PROPEL 3 期数据验证患者报告结局测量信息系统 (PROMIS®) 身体功能问卷在晚发型庞贝病中的有效性

期刊:Journal of Patient-Reported Outcomes
影响因子:2.9
doi:10.1186/s41687-024-00686-z
Kishnani, Priya S; Shohet, Simon; Raza, Syed; Hummel, Noemi; Castelli, Jeffrey P; Sitaraman Das, Sheela; Jiang, Heng; Kopiec, Agnieszka; Keyzor, Ian; Hahn, Andreas
MIS
发表日期：2024
文献求助 收藏

Comparing the efficacy of cipaglucosidase alfa plus miglustat with other enzyme replacement therapies for late-onset Pompe disease: a network meta-analysis utilizing patient-level and aggregate data

比较西帕葡萄糖苷酶α联合米格鲁司他与其他酶替代疗法治疗晚发型庞贝病的疗效：一项利用患者个体数据和汇总数据的网络荟萃分析

期刊:Journal of Comparative Effectiveness Research
影响因子:2.5
doi:10.57264/cer-2024-0045
Shohet, Simon; Hummel, Noemi; Fu, Shuai; Keyzor, Ian; MacCulloch, Alasdair; Johnson, Neil; Castelli, Jeff; Czarny-Ozga, Ilona; Mozaffar, Tahseen; Thom, Howard
发表日期：2024
文献求助 收藏

Histone Demethylases ELF6 and JMJ13 Antagonistically Regulate Self-Fertility in Arabidopsis

组蛋白去甲基化酶ELF6和JMJ13拮抗性地调控拟南芥的自交能力

期刊:Frontiers in Plant Science
影响因子:4.8
doi:10.3389/fpls.2021.640135
Keyzor, Charlie; Mermaz, Benoit; Trigazis, Efstathios; Jo, SoYoung; Song, Jie
信号转导
表观遗传
发表日期：2021
文献求助 收藏

A UK-based cost-utility analysis of indacaterol, a once-daily maintenance bronchodilator for patients with COPD, using real world evidence on resource use

一项基于英国的成本效益分析，利用真实世界资源利用数据，对用于治疗慢性阻塞性肺疾病（COPD）患者的每日一次维持性支气管扩张剂茚达特罗进行了评估。

期刊:Applied Health Economics and Health Policy
影响因子:3.3
doi:10.1007/s40258-013-0021-5
Price, David; Asukai, Yumi; Ananthapavan, Jaithri; Malcolm, Bill; Radwan, Amr; Keyzor, Ian
COPD
慢性阻塞性肺疾病
发表日期：2013
文献求助 收藏

Combination chemotherapy with carboplatin, capecitabine and epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer: a phase I/II trial

卡铂、卡培他滨和表柔比星（ECarboX）联合化疗作为复发性卵巢癌患者二线或三线治疗：一项 I/II 期试验

期刊:British Journal of Cancer
影响因子:6.8
doi:10.1038/sj.bjc.6602879
Rothermundt, C; Hubner, R; Ahmad, T; Gibbens, I; Keyzor, C; Habeshaw, T; Kaye, S; Gore, M
肿瘤
肿瘤免疫
卵巢癌
发表日期：2006
文献求助 收藏